Convulxin, a powerful platelet activator, was isolated from Crotalus durissus terrificus venom, and 20 amino acid N-terminal sequences of both subunits were determined. These indicated that convulxin belongs to the heterodimeric C-type lectin family. Neither antibodies against GPIb nor echicetin had any effect on convulxininduced platelet aggregation showing that, in contrast to other venom C-type lectins acting on platelets, GPIb is not involved in convulxin-induced platelet activation. In addition, partially reduced/denatured convulxin only affects collagen-induced platelet aggregation. The mechanism of convulxin-induced platelet activation was examined by platelet aggregation, detection of timedependent tyrosine phosphorylation of platelet proteins, and binding studies with 125 I-convulxin. Convulxin induces signal transduction in part like collagen, involving the time-dependent tyrosine phosphorylation of Fc receptor ␥ chain, phospholipase C␥2, p72 SYK , c-Cbl, and p36 -38. However, unlike collagen, pp125 FAK and some other bands are not tyrosine-phosphorylated. Convulxin binds to a glycosylated 62-kDa membrane component in platelet lysate and to p62/GPVI immunoprecipitated by human anti-p62/GPVI antibodies. Convulxin subunits inhibit both aggregation and tyrosine phosphorylation in response to collagen. Piceatannol, a tyrosine kinase inhibitor with some specificity for p72 SYK , showed differential effects on collagen and convulxinstimulated signaling. These results suggest that convulxin uses the p62/GPVI but not the ␣ 2 ␤ 1 part of the collagen signaling pathways to activate platelets. Occupation and clustering of p62/GPVI may activate Src family kinases phosphorylating Fc receptor ␥ chain and, by a mechanism previously described in T-and B-cells, activate p72 SYK that is critical for downstream activation of platelets.
, showed differential effects on collagen and convulxinstimulated signaling. These results suggest that convulxin uses the p62/GPVI but not the ␣ 2 ␤ 1 part of the collagen signaling pathways to activate platelets. Occupation and clustering of p62/GPVI may activate Src family kinases phosphorylating Fc receptor ␥ chain and, by a mechanism previously described in T-and B-cells, activate p72 SYK that is critical for downstream activation of platelets.
A large number of C-type lectins from snake venoms have been described over the last few years with effects on hemostasis. While most of these inhibit the function of the coagulation factors and platelet components that they bind to, a few activate platelets by direct or indirect effects. So far all of these have been shown to affect the von Willebrand factor (vWf) 1 platelet GPIb-V-IX axis. They include botrocetin (1) and bitiscetin (2) that bind to and change the conformation of vWf so that it can bind to GPIb and thus activate platelets and alboaggregin B (3) that activates platelets directly by binding to, and presumably clustering, GPIb. A further snake peptide from the venom of some Crotalus species has subunits with a molecular mass similar to the C-type lectins, is a strong activator of platelet phospholipase C, and has been termed convulxin (4 -8) . We have isolated a similar, possibly identical, molecule from Crotalus durissus terrificus venom and show that it belongs to the heterodimeric, C-type lectin family. It activates platelets not via GPIb but through the p62/GPVI component of the platelet collagen receptor, probably by a clustering effect, and induces signals similar to a set of those induced by collagen in platelets.
Several platelet membrane glycoproteins have been implicated as collagen receptors, in particular GPIa-IIa (the ␣ 2 ␤ 1 integrin) (9 -12) , CD36 (13) , and p62/GPVI (14 -16) . Since patients platelets lacking ␣ 2 ␤ 1 do not adhere to or aggregate to collagen (9, 10) , and antibodies against ␣ 2 ␤ 1 block platelet adhesion to immobilized collagen (17) (18) (19) , there is general agreement about the pivotal role of ␣ 2 ␤ 1 in the adhesion of platelets to collagen fibers. Furthermore, it was suggested that platelet adhesion to collagen through the ␣ 2 ␤ 1 integrin induces rapid tyrosine phosphorylation of pp125 FAK ; thus, the ␣ 2 ␤ 1 integrin plays a more direct role in early events of collageninduced platelet activation, other than mediating the initial adhesion to collagen (20, 21) . Many of the platelet responses, induced by collagen, can be induced by synthetic, triple helical, collagen-like peptides based upon typical collagen sequences incorporating multiple glycine-proline-hydroxyproline repeats (22) (23) (24) . These responses are independent of the ␣ 2 ␤ 1 receptor, which shows that receptor(s) other than ␣ 2 ␤ 1 are also involved in the collagen-induced events. A platelet-activating antibody, anti-p62 IgG, found in a patient with autoimmune thrombocytopenia with a selective deficiency in collagen-induced platelet aggregation (25) , immunoprecipitated a 62-kDa protein from normal platelets that was later described as GPVI (14) . All four p62/GPVI-deficient patients, reported so far (14 -16, 25) , showed defective platelet responses only to collagen despite the normal expression of ␣ 2 ␤ 1 . Although CD36, which has been found to be associated with Src family kinases (26) , also may play some role, the fact that patients lacking CD36 adhere normally and aggregate to collagen (27) (28) (29) (30) shows that CD36 is less critical in collagen-induced platelet activation than ␣ 2 ␤ 1 and p62/GPVI. A characteristic of platelet activation by collagen compared via G-protein-linked receptors, such as that for thrombin, is the early engagement of a wide range of tyrosine kinases, phosphatases, and their substrates. Collagen stimulation of platelets results in the phosphorylation of numerous proteins (reviewed in Ref. 31) . Recent reports include collageninduced tyrosine phosphorylation of phospholipase C␥2 (PLC␥2) providing a mechanism for further platelet activation by increasing cytosolic Ca 2ϩ and activating protein kinase C (32, 33) and of the Fc receptor ␥ chain (Fc␥) providing a mechanism for activation of the major tyrosine kinase p72 SYK (24) . Because there are at least two collagen receptors on platelets, but the relative contribution of each to collagen-induced platelet activation has not yet been determined, it is of interest to find platelet agonists that mimic the effect of collagen by acting through only one of the collagen receptors.
Here we show that convulxin, a powerful platelet agonist purified from C. durissus terrificus venom, belongs to the Ctype lectin family, induces platelet activation/aggregation predominantly through one of the collagen receptors, p62/GPVI, and identify some of the signaling molecules involved.
EXPERIMENTAL PROCEDURES
Materials-Lyophilized C. durissus terrificus venom, Protein A-Sepharose, peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies, bovine serum albumin, wheat germ agglutinin (WGA), and Triton X-114 were from Sigma. Sepharose 4B was from Pharmacia Fine Chemicals (Uppsala, Sweden). Iloprost was a kind gift from Schering AG (Zü rich, Switzerland). Na 125 I was from Amersham Corp. (Zü rich, Switzerland), IODO-GEN and the SuperSignal chemiluminescence detection systems were from Pierce. Autoradiography (Fuji RX) films were from Fujifilm (Dielsdorf AG, Switzerland). Methylated type I calf skin collagen was a kind gift from Dr. J. Rauterberg. Piceatannol was from Boehringer Mannheim (Germany). Anti-phosphotyrosine mAb (4G10) was from Upstate Biotechnology Inc. (Lake Placid, NY); anti-p72 SYK (4D10) mAb, anti-c-Cbl (C-15), and anti-pp125 FAK (A-17) polyclonal antibodies and Grb2-(54 -164)-AC were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); anti-Fc␥RII (IV.3) mAb was from Medarex Inc. (Annandale, NJ); AP-1 anti-GPIb mAb was a kind gift from Dr. T. J. Kunicki; SZ-2 anti-GPIb mAb was a kind gift from Dr. C. Ruan; Ib-23 anti-GPIb mAb and Ro44 -9883, a GPIIb-IIIa inhibitor, were kind gifts from Dr. B. Steiner; PTA-1 mAb was a kind gift from Prof. G. Burns; human anti-GPVI polyclonal antibody was a kind gift from Prof. M. Okuma; anti-GP60 (a putative laminin receptor) mAb was a kind gift from Dr. S. Sentoso; mAb 6F1 against ␣ 2 ␤ 1 was a kind gift from Prof. B. Coller; polyclonal antibody against Fc⑀RI␥ was a kind gift from Prof. J.-P. Kinet. Echicetin was purified from lyophilized Echis carinatus sochureki venom (Latoxan, Rosans, France) as described previously (34) . PVDF membranes were PolyScreen from DuPont NEN. Octyl-Nmethylglucamide was from Oxyl Chemie (Bobingen, Germany).
Purification of Convulxin-Lyophilized C. durissus terrificus venom was dissolved at 250 mg/8 ml in 300 mM NaCl, 100 mM ammonium formate, pH 3.5 (buffer A). Insoluble components were removed by centrifugation, and the supernatant was loaded on a Fractogel EMD BioSEC 650 (S) column (16 ϫ 1200 mm; Merck, Darmstadt, Germany) equilibrated with buffer A. At 0.5 ml/min flow rate, 5-ml fractions were collected. Fractions were analyzed by SDS-PAGE/silver staining under nonreducing and reducing conditions and assayed for their ability to induce platelet aggregation. The pH of 100-l aliquots was adjusted to 7.4 by adding 10 l of 1 M Tris, pH 8.5, before the aggregation studies. Fractions that induced platelet aggregation and showed strong 85-kDa (nonreduced) and 14-and 16-kDa (reduced) bands on analysis by SDS-PAGE/silver staining were pooled (15 ml), dialyzed against diluted HCl, pH 3.5, dissolved in 3 ml of buffer A, and rechromatographed under the same conditions as above. Fractions corresponding to the main peak, high purity convulxin, were concentrated to about 20% of their original volume on a Speed-Vac. If a sample became opalescent during this step, a small volume of 0.1% trifluoroacetic acid was added to redissolve the protein. After dialysis against first, 150 mM NaCl, 50 mM phosphate, pH 5.0, second, the same buffer at pH 6.5, and finally, the same buffer or 150 mM NaCl, 50 mM Tris/HCl, pH 7.4, the convulxin was stored at 4°C until used.
Purification and Sequence Analysis of Convulxin Subunits-To 1 volume of 300 g/ml convulxin in 6 M guanidine HCl, 0.1 M Tris, pH 8.0, was added to 1/20 volume 440 mM DTT followed by incubation at 45°C for 30 min. 1/20 volume of 1 M 4-vinylpyridine was added, and after 1 h incubation at room temperature the sample was diluted with 2 volumes of 0.2% trifluoroacetic acid. Modified convulxin subunits were isolated by reverse phase HPLC on a wide pore C4 column (4.6 ϫ 250 mm; J. T. Baker Inc.) using an acetonitrile gradient (0.1% trifluoroacetic acid). N-terminal sequencing of S-pyridylethylated ␣ and ␤ subunits of convulxin was performed on an Applied Biosystem model 477 A pulsedliquid-phase protein sequencer with model 120 A on-line phenylthiohydantoin amino acid analyzer.
Preparation of Partially Reduced/Denatured Convulxin-Partially reduced/denatured convulxin was prepared in the same way as Spyridylethylated ␣ and ␤ subunits of convulxin, omitting 4-vinylpyridine so that the free OSH groups were not chemically modified in these samples. The protein was isolated, free from denaturing and reducing agents, by reverse phase HPLC, freeze-dried, and dissolved in 0.05% trifluoroacetic acid. This treatment resulted in three main fractions corresponding to the two subunits and a fraction that contained both subunits. The ratio of these three fractions varied between preparations.
Labeling of Convulxin with 125 I-Convulxin was labeled by the IODO-GEN procedure (35) . Convulxin, 80 g, and 800 Ci of Na 125 I were added to a glass tube that had been coated with 150 g of IODO-GEN. The reaction mixture was incubated for 30 min at room temperature with gentle agitation. The reaction was stopped by adding 30 mg/ml (final) KI and labeled convulxin was separated from free Na 125 I on a Bio Gel P-6 DG column (0.9 ϫ 16 cm, Bio-Rad) using 5 mg/ml bovine serum albumin, 300 mM NaCl, 50 mM Tris/HCl, pH 7.4. The specific activity of labeled convulxin was between 0.5 and 1.2 ϫ 10 9 cpm/mg.
Computer Analysis of the Sequence Data-Computer analysis of the sequence data was performed on a VAX/VMS system using the suite of programs from the University of Wisconsin Genetics Computer Group.
Protein Determination-Protein determination was performed by the BCA protein assay (Pierce) with bovine serum albumin as a standard.
SDS-PAGE/Silver Staining-SDS-PAGE was performed according to Laemmli (36) , and the gels were silver-stained by the method of Morrissey (37) .
Preparation of Washed Platelets, Platelet Aggregation, and Immunoprecipitations-Human platelets were isolated from buffy coats, less than 20 h after blood collection, obtained from the Central Laboratory of the Swiss Red Cross Blood Transfusion Service. To one buffy coat was added 30 ml of 100 mM citrate, pH 6.5. Platelet-rich plasma and the platelet pellet was isolated by successive centrifugation steps. Platelets were resuspended in 113 mM NaCl, 4.3 mM K 2 HPO 4 , 4.3 mM Na 2 HPO 4 , 24.4 mM NaH 2 PO 4 , 5.5 mM glucose, pH 6.5 (buffer B) and centrifuged at 250 ϫ g for 5 min. The platelet-rich supernatant was centrifuged at 1000 ϫ g for 10 min, and platelets were washed with buffer B once more. Washed platelets were resuspended in 20 mM Hepes, 140 mM NaCl, 4 mM KCl, 5.5 mM glucose, pH 7.4 (buffer C), and the platelet count was adjusted to 5 ϫ 10 8 platelets/ml by dilution with buffer C. Samples were kept at room temperature until used for aggregation studies. Platelet aggregation was monitored by light transmission in an aggregometer (Lumitec, France) with continuous stirring at 1100 rpm at 37°C. Platelets were preincubated in buffer containing 2 mM CaCl 2 at 37°C for 2 min before starting the measurement by adding the samples for analysis. For immunoprecipitation, aliquots (700 l, 5 ϫ 10 8 platelets/ml) of control, resting as well as activated platelets were solubilized in phosphate-buffered saline containing 1.2% Triton X-100 with 1 mM phenylmethylsulfonyl fluoride, 5 mM EDTA, 2 mM N-ethylmaleimide (NEM), 2 mM benzamidine, and 2 mM sodium orthovanadate. After centrifugation, platelet lysates, precleared with Protein A-Sepharose, were stirred for 2 h with specific antibodies before adding 20 l of Protein A-Sepharose followed by 6 -8 h incubation.
Triton X-114 Phase Separation and Wheat Germ Agglutinin Affinity Chromatography-Human platelets were isolated from 10 buffy coats as described previously (38) . The platelet count was adjusted to 1 ϫ 10 9 platelets/ml with 20 mM Tris/HCl, pH 7.4, 10 mM EDTA, 154 mM NaCl (TENA buffer), and Triton X-114 phase separation was performed as described previously (39) . The Triton phase was diluted 10 times with 2 mM sodium orthovanadate, 2 mM NEM, 4 mM EDTA, 20 mM NaCl, 10 mM Tris/HCl, pH 7.4 (buffer D), and centrifuged at 10,000 ϫ g for 30 min at 4°C. The supernatant was applied to a column of WGA-Sepharose 4B (2.6 ϫ 15 cm, 1 mg of WGA/ml of Sepharose 4B) equilibrated with buffer D. The column was washed intensively with buffer D containing 0.1% octyl-N-methylglucamide. The bound material was eluted with 2.5% N-acetylglucosamine in buffer D containing 0.5% octyl-Nmethylglucamide. Fractions containing glycoproteins were pooled, concentrated 10-fold by ultrafiltration, dialyzed against water, and freezedried. The sample was dissolved in 4 ml of phosphate-buffered saline, pH 7.2, containing 2 mM sodium orthovanadate, 2 mM NEM, 4 mM EDTA. 750-l aliquots of this preparation were used for immunoprecipitations.
Identification of 125 I-Labeled Convulxin-binding Proteins in Immunoprecipitated Platelet Proteins by an Affinity Blotting
Method-Aliquots (750 l) of platelet glycoprotein samples (see above) were incubated at 4°C for 3 h with 5 l of anti-PTA1, anti-p62/GPVI, and anti-GP60 antibodies followed by incubation with 5 mg of Protein ASepharose at 4°C overnight. The Protein A-Sepharose samples were washed four times by centrifugation in ice-cold phosphate-buffered saline, pH 7.2, containing 2 mM sodium orthovanadate, 2 mM NEM, and 4 mM EDTA. The samples were boiled in 40 l of 2% SDS, 50 mM Tris/HCl, pH 8.0, for 5 min and centrifuged, and the supernatants were electrophoresed on a 7-17% gradient SDS-polyacrylamide gel. Proteins were transferred electrophoretically to PVDF membrane, and convulxin-binding proteins were detected using 125 I-labeled convulxin. The membranes were incubated with 1 g/ml labeled convulxin in 2% bovine serum albumin, 300 mM NaCl, 50 mM Tris/HCl, pH 7.4, for 3 h followed by washing 7 times with the same buffer for 30 min. The membranes were rinsed with water, dried, and radioactive labeling detected by autoradiography using a PhosphorImager (Molecular Dynamics).
RESULTS
Convulxin Is a Heterodimeric C-type Lectin-Convulxin was purified from lyophilized C. durissus terrificus venom by a two-step gel filtration method (Fig. 1 ). The final product showed an 85-kDa broad band under nonreducing conditions and two bands, 14 and 16-kDa, under reducing conditions when analyzed by SDS-PAGE/silver staining (see inset in Fig. 1B ). Treatment with DTT alone under nondenaturing conditions was not sufficient to separate the subunits by reverse phase HPLC. However, S-pyridylethylation allowed a separation of the subunits by reverse phase HPLC. Fractionation of reduced S-pyridylethylated convulxin subunits is shown in Fig. 2 . Peaks in the 3-10-min interval represent non-protein peaks originated from the reagents used for reduction and S-pyridylethylation. Fractions 1 and 2 contained homogenous single chain proteins with apparent M r of 16 and 14, respectively, on analysis by SDS-PAGE/silver staining (see inset of Fig. 2) . Following the nomenclature of Marlas (7), we called the 14-kDa protein (fraction 2) the ␣ subunit and the 16-kDa protein (fraction 1) the ␤ subunit. N-terminal sequence analysis gave the 20 amino acid sequence GFCCPSHWSXYDRYCYKVFK for the ␣ subunit and GLHCPSDWYYYDQHCYRIFN for the ␤ subunit. Computer analysis of the sequences showed that convulxin is a heterodimeric C-type lectin with strong sequence similarity to other venom C-type lectins (Fig. 3) .
Convulxin Does Not Act through GPIb or ␣ 2 ␤ 1 -Convulxin is a powerful platelet agonist and, at concentrations as low as 3-10 ng/ml, induced maximal aggregation of isolated human platelets (data not shown). The strong sequence similarity to C-type lectins that bind to GPIb suggested that GPIb might be involved in platelet activation induced by convulxin. However, neither antibodies against GPIb (Ib-23, SZ-2, and AP-2) nor echicetin, a snake venom C-type lectin that binds to GPIb and inhibits platelet agonists acting through GPIb (34), had any effect on convulxin-induced platelet aggregation (data not shown). In addition, partially reduced/denatured convulxin had no effect on ristocetin-vWf-induced platelet agglutination (see below). These data show that GPIb is not involved in convulxininduced platelet activation. A mAb against ␣ 2 ␤ 1 (6F1), which inhibits collagen-induced platelet activation, had little effect on convulxin-induced platelet aggregation (data not shown). Partially Reduced/Denatured Convulxin Only Affects Collagen-induced Platelet Aggregation-Neither of the reduced, Spyridylethylated convulxin subunits activated platelets (data not shown), suggesting that the platelet activation effect of convulxin requires its native conformation rather than a linear sequence in its subunits. Neither incubation of convulxin with up to 50 mM DTT at 37°C for 30 min nor freezing and thawing the convulxin sample in the presence of 50 mM DTT decreased the ability of convulxin to aggregate platelets. After reduction of convulxin under denaturing conditions, in the presence of 6 M guanidine HCl, reverse phase HPLC gave three main peaks corresponding to the two subunits and a fraction that contained both subunits. The ratio of these peaks varied between preparations (n ϭ 10, data not shown). None of these partially reduced/denatured convulxin subunits induced platelet aggregation or signal transduction. Seven out of ten preparations, containing either ␣, ␤, or both subunits, had no effect on platelet aggregation induced by various agonists. However, the others inhibited convulxin-induced aggregation as well as collagen-induced platelet aggregation in a concentration-dependent manner, whereas they had no effect on platelet aggregation induced by thrombin or ristocetin-vWf. These data show that convulxin and its two subunits bind to a common receptor that is involved in collagen activation of platelets.
Convulxin Binds to p62/GPVI-The fact that the N-terminal sequences of convulxin are rich in tyrosine suggested that it might be readily labeled by 125 I without affecting its biological activity, and this proved to be the case. The platelet membrane protein binding 125 I-labeled convulxin was identified. It is a 62-kDa hydrophobic, platelet membrane glycoprotein (Fig. 4,  lane 1 ) present in the Triton phase after Triton X-114 phase separation of platelet membrane proteins that binds to WGA (Fig. 4, lane 2) .
125
I-Labeled convulxin binds strongly only to the 62-kDa protein immunoprecipitated with anti-p62/GPVI antiserum (Fig. 4, lane 6) and not to other platelet membrane glycoproteins with similar molecular masses and physicochemical properties immunoprecipitated by specific antibodies (Fig.  4, lane 4 , anti-PTA-1 mAb and lane 5, anti-GP60 laminin receptor mAb). This argues convincingly that the p62/GPVI collagen receptor is the binding site for convulxin on platelets. Fig. 5 shows a time range of tyrosine phosphorylation for platelets activated by 5 mg/ml collagen compared with that with 30 ng/ml convulxin. These relative amounts were chosen because they gave comparable rates of platelet aggregation as estimated by the slope of the aggregometer curve. Such aggregation slopes are often used as the basis for comparison of activation rates. With convulxin several proteins are phosphorylated more rapidly but also more intensely than with collagen. These include Fc␥, p36 -38, p72 SYK , PI3K, c-Cbl, and PLC␥2. These tyrosine phosphorylations induced by convulxin were not inhibited by raising the adenylate cyclase level by adding Iloprost (final concentration 0.15 nM) to the platelet suspension 5 min before the agonist (data not shown). These components were identified by immunoprecipitation with specific antibodies or, in the case of p36 -38, by precipitation with a GST-Grb2 SH2 fusion protein. Some of these data are shown in Fig. 6 . In Fig. 6A the first three lanes show the tyrosine phosphorylation pattern at 30 s of resting platelets, platelets activated by collagen, and platelets activated by convulxin, respectively, and the following three lanes show the phosphotyrosine proteins binding to GST-Grb2 SH2 domain from these platelet preparations. This clearly identifies 
Tyrosine Phosphorylation Signal Transduction by Convulxin Compared with Collagen-

FIG. 5. Time dependence of tyrosine phosphorylation in proteins from platelets activated by collagen or convulxin.
Washed platelets (700 l) were stirred at 1100 rpm at 37°C. After addition of 3 g of collagen or 30 ng of convulxin, aliquots were removed at the times indicated and dissolved in SDS buffer containing inhibitors. After separation by SDS-PAGE gel electrophoresis (7-20% acrylamide gradient) and transfer to PVDF membranes, the proteins were incubated with the anti-phosphotyrosine antibody 4G10 before detection by a peroxidaselinked second antibody and chemiluminescence.
the tyrosine-phosphorylated p36 -38 band present in the platelets as a major Grb2 SH2-binding protein that is much more tyrosine-phosphorylated in convulxin-activated platelets and is distinct from the immunoprecipitated Fc␥RIIA receptor that has a higher molecular mass as shown in the five lanes on the right. Thus p36 -38 is perhaps the human equivalent of, or at least related to, the Lnk adaptor protein (40) . Fc␥RIIA also shows raised levels of tyrosine phosphorylation after platelet activation by collagen or convulxin but much less than p72 SYK , Fc␥, and c-Cbl. Similarly, in Fig. 6B the upper bands show the level of tyrosine phosphorylation in immunoprecipitates from resting, collagen-, and convulxin-activated platelets, with p72 SYK , Fc␥, and c-Cbl antibodies, respectively, and the lower bands show the same blots after stripping and restaining with the corresponding antibodies to show that equal amounts of each component were immunoprecipitated from each platelet preparation. p72 SYK , Fc␥, and c-Cbl are all tyrosine-phosphorylated after platelet activation by collagen compared with virtually nil or very low levels in resting platelets but are even more dramatically tyrosine-phosphorylated after platelet activation by convulxin. Fig. 6C shows that whereas convulxin is a powerful activator of pp125 FAK , this was delayed compared with collagen and was completely inhibited in the presence of 1 M Ro44-9883, a specific, efficient inhibitor of fibrinogen binding to GPIIb-IIIa (41), indicating that the activation of pp125 FAK by convulxin is via activation of GPIIb-IIIa and release and binding of fibrinogen rather than via ␣ 2 ␤ 1 that is an early event in platelet activation by collagen and is not prevented by GPIIb-IIIa inhibitors. In some cases, however, the collagen induced a more rapid and stronger earlier phosphorylation than convulxin. This was the case with a band at 125 kDa (Fig. 5) , identified as p125 FAK in Fig. 6C , and with so far unidentified bands at about 32 and 28 kDa (Fig. 5) . As well as p36 -38, GST-Grb2 SH2 fusion protein precipitated an additional band at about 30 kDa from a lysate of collagen-activated platelets but not from convulxin-activated platelets (Fig. 6A) .
Partially Reduced/Denatured Convulxin Subunits Inhibit Aggregation and Tyrosine Phosphorylation Signal Transduction by Collagen-Partially reduced/denatured convulxin subunits inhibit collagen-induced platelet aggregation in a dosedependent way. Fig. 7A shows the aggregation response to collagen in the presence and absence of an intermediate dose of FIG. 6 . Identification of bands with increased tyrosine phosphorylation in platelets after activation by collagen or convulxin. A, control platelets or platelet suspension activated by collagen (coll) or convulxin (con) were lysed in Triton X-100 buffer containing inhibitors. Aliquots were incubated with GST-Grb2 SH2 agarose conjugate or immunoprecipitated with anti-Fc␥RIIA antibodies. The proteins eluted from the GST-Grb2 SH2 agarose and the immunoprecipitates were separated by SDS-PAGE gel electrophoresis (7-20% acrylamide gradient). After transfer, the proteins were incubated with 4G10 anti-phosphotyrosine antibody and detected by a peroxidaselinked second antibody and chemiluminescence. B, control platelets or platelets suspension activated by collagen or convulxin for 30 s were lysed in Triton X-100 buffer containing inhibitors. Aliquots were immunoprecipitated with antibodies against p72 SYK , Fc␥, or c-Cbl. After SDS-PAGE and Western blotting, the proteins were detected with 4G10 anti-phosphotyrosine antibody. The membranes were stripped and treated with anti-p72 SYK , anti-Fc␥, or anti-c-Cbl antibodies. C, control platelets or platelet suspension were activated by convulxin in the presence of 1 M Ro44 -9883, a GPIIb/IIIa inhibitor, and by convulxin or collagen. Aliquots were immunoprecipitated with antibodies against pp125 FAK . After SDS-PAGE and transfer to PVDF membrane, the proteins were detected with 4G10 anti-phosphotyrosine antibody. The membranes were stripped and treated with anti-pp125 FAK antibody.
FIG. 7. Aggregation response and time dependence of tyrosine phosphorylation in proteins from platelets activated by collagen or by collagen in the presence of convulxin subunits.
Washed platelets (700 l) were stirred at 1100 rpm at 37°C in the presence or absence of 200 ng of convulxin subunits. After 90 s, 1 g of collagen was added. A, aggregation curves. B, aliquots were removed at the times indicated and dissolved in SDS buffer containing inhibitors. After separation by SDS-PAGE gel electrophoresis (7-20% acrylamide gradient) and transfer to PVDF membranes, the proteins were incubated with the anti-phosphotyrosine antibody 4G10 before detection by a peroxidase-linked second antibody and chemiluminescence. a typical preparation of subunit(s). In the presence of the subunit(s) the aggregation is rapid at first but quickly reaches a maximum and reverses, leading to platelet disaggregation. Fig.  7B shows the time range tyrosine phosphorylation profile. Both subunits gave similar effects. Compared with the collagen control, in the presence of the subunits the tyrosine phosphorylation is slower, much less intense, of shorter duration, and those bands that do show clear but brief increases included those corresponding to pp125 FAK and the 32-and 28-kDa groups. Tyrosine phosphorylation of bands corresponding to p36 -38 and to Fc␥ were strongly inhibited and did not increase during the aggregation phase.
Effects of Piceatannol on Signaling through Tyrosine Phosphorylation by Convulxin Compared with Collagen-As previously reported (42) piceatannol inhibits both platelet aggregation and tyrosine phosphorylation induced by collagen. In the case of convulxin, however, the aggregation was not completely inhibited at doses of convulxin giving an equivalent aggregation rate, whereas that of collagen was completely inhibited. In this experiment lower amounts of the agonists were used to be able to inhibit convulxin-induced aggregation at relevant doses of piceatannol. With convulxin a brief reversible aggregation similar to, but weaker than, that shown in Fig. 7A for the convulxin subunits was observed. In addition, unlike with collagen, the tyrosine phosphorylation in general was not inhibited and, compared with control, convulxin-activated platelets lasted longer (Fig. 8 ). Those proteins with prolonged tyrosine phosphorylation included p36 -38, Fc␥, and several unidentified bands including two at about 80 and 180 kDa. On the other hand, tyrosine phosphorylation of some bands was inhibited by piceatannol in convulxin-activated platelets (Fig. 8B) . These included unidentified bands at 85 and 120 kDa. Tyrosine phosphorylation of p72 SYK lasted longer in collagen than in convulxin-activated platelets, peaking in the latter between 10 and 30 s. Tyrosine phosphorylation of p72 SYK was clearly inhibited by piceatannol in collagen-activated platelets. In convulxinactivated platelets it appeared inhibited at 10 s but less so at 30 s, otherwise the time course was not affected.
DISCUSSION
The venom from several Crotalus species contains a heterodimeric protein that is a powerful platelet activator. We isolated, separated, and determined the N-terminal sequence, 20 amino acids, of the ␣ and ␤ subunits of this protein purified from C. durissus terrificus venom and show that this protein belongs to the C-type lectin family, with sequences most similar to alboaggregin B. The previously published very short N-terminal sequences of the protein identified and defined as convulxin in the venom of Crotalus durissus cascavella, GFRPD for both subunits (7), are not identical to the sequences we found. Thus, while it is likely to be the same protein and would appear to have similar properties, at the moment we cannot exclude that it is a closely related protein since many snake venoms do contain such families of proteins, and the relative amounts may vary depending on the place where the snake comes from and the major prey in that area (43) . In the absence of information to the contrary we shall use the name convulxin here. Because so far the only C-type lectins that activate platelets do so via the vWf-GPIb axis, we first of all checked if this was true for convulxin, but the platelet activation was inhibited neither by specific anti-GPIb antibodies that inhibit platelet-activation by vWf-ristocetin nor by echicetin, another C-type lectin from E. carinatus venom demonstrated to bind to GPIb and to inhibit platelet activation (34) .
Earlier results showing that platelet activation by both collagen and convulxin was antagonized by methylation inhibitors that did not interfere with other platelet agonists, such as thrombin, ADP, or Ca 2ϩ ionophore A 23187 (44, 45) , and specific crossed desensitization between convulxin-and collagenactivated platelets (5), suggested that convulxin and collagen might share common receptors. The mechanism of platelet activation by collagen is still controversial. At least three molecules have been implicated as receptors, GPIa-IIa (the integrin ␣ 2 ␤ 1 ) (9 -12), CD36 (13) , and p62/GPVI (14 -16). Accumulated evidence points to a major role of ␣ 2 ␤ 1 in adhesion, whereas p62/GPVI may be more important in activation, shape change, and secretion. To find out whether convulxin receptors might be involved, we prepared purified subunits of convulxin under conditions where we expected at least some retention of activity and examined their effect on collagen-induced platelet activation. There has been some controversy about the functionality of reduced, separated subunits of snake venom C-type lectins. For example, among those recognizing GPIb, echicetin ␤ was shown to retain activity and to inhibit thrombin and vWf activation of platelets (46) , whereas the isolated subunits of GPIb-binding protein were inactive (47) . An explanation of these differences might be that the active preparations were probably only partly reduced and could, at least partly, refold to an active conformation, whereas the inactive preparations had FIG. 8 . Time dependence of tyrosine phosphorylation in proteins from platelets activated by collagen and convulxin in the presence and absence of piceatannol. Washed platelets (700 l) were stirred at 1100 rpm at 37°C for 7 min in the presence of 25 M piceatannol. After addition of 1 g of collagen or 10 ng of convulxin, aliquots were removed at the times indicated and dissolved in SDS buffer containing inhibitors. After separation by SDS-PAGE gel electrophoresis (7-20% acrylamide gradient) and transfer to PVDF membranes, the proteins were incubated with the anti-phosphotyrosine antibody 4G10 before detection by a peroxidase-linked second antibody and chemiluminescence.
been efficiently reduced and alkylated, so that refolding and disulfide bridge formation were effectively prevented. Thus it is essential not to block the free OSH groups to allow reformation of disulfide bridges after separation of the subunits. Partially reduced/denatured samples containing ␣, ␤, or both subunits of convulxin did not induce platelet aggregation or tyrosine phosphorylation (Fig. 7) , but they did inhibit platelet aggregation induced by collagen while having no effect on platelet aggregation induced by thrombin or vWf-ristocetin, strongly implicating the collagen receptor(s) in convulxin-induced platelet activation. However, a mAb to ␣ 2 ␤ 1 that blocks collagen-induced platelet aggregation had only very weak effects on convulxininduced aggregation. A remaining candidate for the convulxin receptor is p62/GPVI.
125 I-Labeled convulxin bound to a 62-kDa membrane glycoprotein and to a similar sized molecule in the material immunoprecipitated by anti-p62/GPVI antibodies known to activate platelets by a collagen-like mechanism (48) but not to material immunoprecipitated by antibodies recognizing other platelet membrane glycoproteins of similar molecular mass and physicochemical properties (anti-PTA-1 or anti-GP60 putative laminin receptor antibodies). Thus, the evidence supports a model where both subunits of convulxin bind to the p62/GPVI collagen receptor. This heterodimeric binding to the same protein together with the fact that convulxin exists as disulfide-linked hexamers, ␣ 3 ␤ 3 , which are able to form even larger structural units up to 150 Å in diameter (6, 7), immediately suggests an activation mechanism based on cross-linking and clustering p62/GPVI. It has been suggested many times that collagen with its repetitive structure and many available binding sites may also work by such a mechanism. In addition, signal transduction by convulxin shows many similarities to that induced by collagen and, as recently shown, by collagenlike peptides (23) . Important molecules identified in collageninduced signaling include the ␥ subunit of Fc⑀RI, p72 SYK , PLC␥2, and a p36 -38 molecule (24) . In platelets activated by convulxin these are all rapidly tyrosine-phosphorylated as well suggesting that, as with collagen itself, it is the clustering of p62/GPVI that has a major role in activating these pathways. Studies with collagen, collagen-like peptides, and WGA have all shown that Fc␥ and PLC␥2 are rapidly phosphorylated/ activated, and it has been suggested that p62/GPVI may be tightly associated with Fc␥ and activates Src family kinases by a mechanism previously described in T-and B-cells (reviewed in Ref. 49) leading to activation of p72 SYK that is critical for downstream engagement of the enzymes involved in further platelet stimulation (24) . The results described above clearly indicate that convulxin interacts with platelets predominantly via the p62/GPVI receptor, whereas collagen uses additional receptors including GPIa/IIa (␣ 2 ␤ 1 ) and possibly CD36. It might therefore be expected that the signal transduction resulting from engagement of these receptors would show related differences. Overall the pattern of tyrosine phosphorylation in platelets activated by convulxin compared with collagen did show considerable similarity indicating that they do share common pathways. However, there were also marked differences in the strength and timing of the signals. A problem in comparing such signals is choosing an appropriate concentration of reagent to use in each case. In this case we decided to use amounts that give comparable rates of aggregation as reflected by the slope of their aggregation curves. The rate of aggregation reflects the final confluence of signaling pathways in activation of platelets. In the convulxin-activated platelets Fc␥, p36 -38, p72 SYK , PI3K, c-Cbl, and PLC␥2 show a more rapid and more intense phosphorylation compared with platelets activated with collagen. Logically these components should then be linked to the p62/GPVI receptor pathway. On the other hand, bands at 125, 32, and 28 kDa were less tyrosine-phosphorylated than those in the corresponding controls activated by collagen and should therefore be related to other receptors such as ␣ 2 ␤ 1 . In collagen-activated platelets the 125-kDa band was shown to be pp125 FAK , and it was also found to be strongly tyrosine-phosphorylated later in convulxin-activated platelets (Fig. 6) . However, since this could be prevented by a specific GPIIb-IIIa inhibitor, it is clearly related to release of fibrinogen and binding to activated GPIIb-IIIa in convulxin-activated platelets and not to binding to ␣ 2 ␤ 1 as with collagen. It was also of interest to note that when platelet aggregation to collagen was blocked by convulxin subunits the tyrosine phosphorylation of the pp125 FAK , 32-, and 28-kDa bands was markedly less affected suggesting that, in this case, the bulk of the signal transduction occurs via ␣ 2 ␤ 1 but that it was not adequate to maintain the platelets in an activated state and they therefore disaggregated. This distinctive use by convulxin of the p62/ GPVI pathway but not the ␣ 2 ␤ 1 is also supported by the lack of effect of anti-␣ 2 ␤ 1 antibodies on convulxin-induced platelet aggregation as well as the strong parallels with the effects of the collagen-like peptides and the anti-p62/GPVI antibodies on platelets. Activation of platelets with collagen-like peptides that are also thought not to use the ␣ 2 ␤ 1 receptor gave a very similar tyrosine phosphorylation pattern to that obtained with convulxin (23, 24) . The collagen-like peptides also gave enhanced and rapid tyrosine phosphorylation of bands in the positions of p36 -38, p72 SYK , PI3K, c-Cbl, and PLC␥2, whereas bands at 125, 32, and 28 kDa were also less tyrosine-phosphorylated than those in the corresponding controls activated by collagen (23) .
Recently, it was demonstrated that the tyrosine kinase inhibitor, piceatannol, which shows specificity for p72 SYK (50) , was an efficient inhibitor of collagen-induced platelet aggregation and, indeed, inhibited tyrosine phosphorylation of signal transduction components (42) . Surprisingly, with convulxin as agonist it showed some dramatically different effects causing rather a prolonged phosphorylation of several components including p36 -38. This would indicate that in convulxin-activated platelets p72 SYK has a major role in activation of tyrosine phosphatases, whereas in collagen-activated platelets there are alternative pathways for activation of these phosphatases via other receptors (51) or, alternatively, that piceatannol can also inhibit directly a phosphatase activated by the p62/GPVI pathway, whereas the other pathways activate additional noninhibitable phosphatases. It might also indicate that p72 SYK is not involved in phosphorylating p36 -38 in convulxin-activated platelets. It was also recently shown that anti-␣ 2 ␤ 1 antibodies block tyrosine phosphorylation of both p72 SYK and PLC␥2 by collagen (42) . On the other hand, cross-linking anti-␣ 2 ␤ 1 antibodies activated platelets and increased phosphorylation of both p72 SYK and PLC␥2. However, this involved the Fc␥RIIA receptor, and F(ab) 2 fragments were not stimulatory. There is thus good evidence linking p62/GPVI with Fc␥ and p72 SYK in a common pathway that resembles that of the T-and B-cell receptors. Both p36 -38-like molecules and c-Cbl have been closely implicated in these latter receptor mechanisms (52, 53) .
The fact that agents such as convulxin or the collagen-like peptides are able to activate platelets efficiently and in a very similar way to collagen raises the question why ␣ 2 ␤ 1 and CD36 are necessary in physiological situations. The main evidence for a role for these other receptors comes from inhibitory studies with specific antibodies. The CD36 negative platelets respond relatively normally to collagen (27) (28) (29) (30) , and it was never possible to check if the ␣ 2 ␤ 1 -deficient platelets (9, 10) had normal levels of p62/GPVI nor was signal transduction investigated. However, since collagen contains p62/GPVI binding sites, supported by the poor response to collagen of p62/GPVIdeficient platelets, as well as the inhibitory effect of the convulxin subunits on collagen-induced activation and the characteristics of the platelet response to collagen-like peptides, why are the ␣ 2 ␤ 1 receptors necessary? There are several plausible answers. The ␣ 2 ␤ 1 receptors are certainly necessary for platelet adhesion (19) . In addition, the p62/GPVI-binding sites on collagen may be cryptic and require the binding of the ␣ 2 ␤ 1 receptor to expose them correctly to the p62/GPVI receptor. This is supported by evidence that the ␣ 2 ␤ 1 receptor has less critical requirements for binding collagen than does p62/GPVI, which needs intact tertiary and quaternary structures (22) . Alternatively, since both receptors appear capable of mediating signals, the activating potential may depend upon an adequate matrix of platelet binding sites of both types being present on collagen to ensure that the receptors are clustered and brought into sufficient proximity for activation mechanisms to occur. If either receptor (or binding site) is blocked then an adequate clustering is not attained and activation is prevented. This would explain why ligands, containing one type of binding site presented in multimeric form in a more closely packed arrangement, such as in convulxin or the collagen-like peptides, are such potent activators of platelets. It will be of considerable interest to see if collagen-like peptides containing multimeric forms of the ␣ 2 ␤ 1 -binding motif from collagen can also activate platelets directly or whether this motif is only effective in conjunction with p62/GPVI-or Fc␥RIIA-binding motifs. It was also recently shown, in one of the patients with p62/GPVIdeficient platelets, that while collagen did not activate p72 SYK it did activate c-Src kinase normally (54) , implying that this occurs via other receptors, presumably ␣ 2 ␤ 1 . The importance of ␣ 2 ␤ 1 may also be associated with its primary role in adhesion and with the necessity to modulate the extremely powerful responses induced via p62/GPVI alone. Damaged subendothelial tissue probably exposes sites on collagen for both types of receptor. It is important that platelet activation after binding to collagen should be limited in extent and should be responsive to feedback mechanisms, both positive and negative; hence, under physiological conditions a two-receptor mechanism provides the required flexibility.
The finding that convulxin binds to and acts predominantly, if not exclusively, via p62/GPVI adds it to anti-p62/GPVI antibodies and collagen-like peptides as p62/GPVI-specific reagents. The unique structure and properties of convulxin offer considerable opportunities for the isolation and characterization, as well as for further exploration of the signaling responses of this important receptor.
